Traditional flu vaccines may be missing a critical component in pandemic preparedness—the ability to activate mucosal immunity in the respiratory tract where influenza viruses first establish infection. This gap becomes particularly concerning as avian flu strains like H5N1 and H7N9 continue evolving with pandemic potential.
Researchers developed RNA replicon vaccines packaged in nanostructured lipid carriers that can be administered either through conventional muscle injection or intranasally. When tested against the highly pathogenic H5N1 Vietnam strain and H7N9 Anhui strain in mouse models, intranasal delivery generated both systemic antibody responses and robust mucosal immunity in respiratory tissues. The muscle-injected version produced only systemic responses with no detectable mucosal protection. Both monovalent and bivalent formulations provided complete protection against severe disease and death in ferret challenge studies.
This represents a significant advancement in vaccine delivery technology that could reshape pandemic response strategies. Most current influenza vaccines rely on systemic immunity alone, potentially leaving the initial site of viral entry—nasal passages and upper respiratory tract—vulnerable to infection and transmission. The replicon platform's flexibility allows rapid adaptation to emerging strains while the lipid carrier enables mucosal delivery without requiring specialized administration equipment. However, the transition from animal models to human trials will be critical for validating both safety and efficacy. The approach could prove especially valuable for pandemic scenarios where blocking transmission at mucosal surfaces becomes as important as preventing severe systemic disease.